CPP MasterClass Programs

Explore Upcoming Speaker Programs Led by Renowned HCPs – REGISTER Today!

Join our exclusive educational series featuring expert insights from top clinicians on managing central precocious puberty (CPP) with Triptodur® (triptorelin). Whether you’re a pediatric endocrinologist, primary care provider, or nurse, there’s a session tailored just for you. Details included below.

CPP MasterClass: Advancing Pediatric Endocrinology

Description: A deep dive for pediatric endocrinologists into the latest in CPP management.

  • Review clinical trial data on the safety and efficacy of Triptodur® (triptorelin) for the treatment of CPP.
  • Explore differential diagnoses of precocious puberty and the latest findings on the potential benefits of extending GnRHa treatment
  • Learn what happens to timing of menarche, growth rates, and long-term BMI after treatment with GnRHas

Presented by: Quentin Van Meter, MD

Date & Time: August 12, 2025, at 6:00 PM EST

Register Now

Presented by: Lisa Knight, MD or Joshua Yang, MD

Date & Time: October 7, 2025, at 12:00 PM EST

Register Now

Spotlight on Early Puberty: Recognizing and Referring CPP

Description: Designed for pediatricians and primary care providers.

  • Review the early signs of CPP
  • Explore practical diagnostic strategies; includes a case study as an exercise in diagnosing CPP
  • Learn about diagnostic paths that can help differentiate CPP from other forms of early puberty—empowering you to make timely, confident decisions for your patients on when and how to diagnose and when to refer to a specialist
  • Explore Triptodur® (triptorelin) for the treatment of CPP

Presented by: Jose David Gamez-Godoy, MD

Date & Time: September 18, 2025, at 1:00 PM EST

Register Now

Presented by: Lisa Knight, MD or Joshua Yang, MD

Date & Time: November 12, 2025, at 6:00 PM EST

Register Now

Nurse Essentials: Confidently Administering Triptodur®

Description: A hands-on, practical workshop for nurses.

  • Triptodur reconstitution and administration
  • Live demo, expert tips, and strategies
  • Interactive Q&A
  • Become a champion for patient comfort and care

Presented by: Shannon Dansby, Clinical RN III

Date & Time: September 24, 2025, at 10:00 AM EST

Register Now

Presented by: Amy Eaton, RN, MSN

Date & Time: November 4, 2025, at 12:00 PM EST

Register Now

Nurse Connect: Supporting Families on the Triptodur® Journey

Description: This session gives a brief overview of Triptodur for the treatment of CPP and also equips nurses with communication tools and resources to support families and children starting Triptodur.

  • Review Triptodur dosing and administration
  • Learn how to address questions and ease anxieties
  • Use the Trip the Dinosaur starter kit to create a welcoming experience

Presented by: Shannon Dansby, Clinical RN III

Date & Time: October 21, 2025 at 10:00 AM EST

Register Now

Beyond the Prescription: The Triptodur CareSM Experience

Description: Open to all healthcare team members, this program demystifies Triptodur® (triptorelin) coverage, specialty pharmacy coordination, and patient assistance programs.

  • Discover how the Triptodur CareSM team makes access and adherence easier for everyone
  • Review Triptodur for the treatment of CPP

Presented by: Lisa Knight, MD and Shannon Dansby, Clinical RN III

Date & Time: December 9, 2025, at 12:00 PM EST

Register Now

PP-TRIP-US-1321

IMPORTANT SAFETY INFORMATION FOR TRIPTODUR

INDICATION

TRIPTODUR is indicated for the treatment of pediatric patients 2 years of age and older with central precocious puberty (CPP).

IMPORTANT SAFETY INFORMATION

Contraindications

TRIPTODUR is contraindicated in:

  • Individuals with a known hypersensitivity to triptorelin or any other component of the product, or other GnRH agonists or GnRH.
  • Women who are or may become pregnant. Expected hormonal changes that occur with TRIPTODUR treatment increase the risk for pregnancy loss and fetal harm when administered to a pregnant woman. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be advised of the potential risk to the fetus.

Warnings and Precautions

Initial Rise of Gonadotropins and Sex Steroid Levels – During the early phase of therapy, gonadotropins and sex steroids rise above baseline because of the initial stimulatory effect of the drug. Therefore, a transient increase in clinical signs and symptoms of puberty, including vaginal bleeding, may be observed during the first weeks of therapy or after subsequent doses.

Psychiatric Events – Psychiatric events have been reported in patients taking GnRH agonists. Postmarketing reports with this class of drugs include symptoms of emotional lability, such as crying, irritability, impatience, anger, and aggression. Monitor for development or worsening of psychiatric symptoms during treatment with TRIPTODUR.

Convulsions – Postmarketing reports of convulsions have been observed in patients receiving GnRH agonists, including triptorelin. These included patients with a history of seizures, epilepsy, cerebrovascular disorders, central nervous system anomalies or tumors, and patients on concomitant medications that have been associated with convulsions such as bupropion and SSRIs. Convulsions have also been reported in patients in the absence of any of the conditions mentioned above.

Pseudotumor Cerebri (idiopathic intracranial hypertension) – has been reported in pediatric patients receiving GnRH agonists, including triptorelin. Monitor patients for signs and symptoms of pseudotumor cerebri, including headache, papilledema, blurred vision, diplopia, loss of vision, pain behind the eye or pain with eye movement, tinnitus, dizziness, and nausea.

Adverse Reactions

In clinical trials for TRIPTODUR, the most common adverse reactions (≥4.5%) are injection site reactions, menstrual (vaginal) bleeding, hot flush, headache, cough, and infections (bronchitis, gastroenteritis, influenza, nasopharyngitis, otitis externa, pharyngitis, sinusitis, and upper respiratory tract infection).

To report SUSPECTED ADVERSE REACTIONS, contact Azurity Pharmaceuticals, Inc. at 1-800-461-7449, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

The Important Safety Information does not include all the information needed to use TRIPTODUR safely and effectively. For additional safety information, please consult the full Prescribing Information for TRIPTODUR.